NextPharma Technologies Announces Development Agreement With EUCODIS
London, UK – 24th of February 2007
NextPharma Technologies - a leading provider of product development and contract manufacturing outsourcing services to the rapidly growing biotech and pharmaceutical industry, is delighted to report that it has reached a development agreement with the biotech company Eucodis GmbH, Vienna by which Nextpharma will develop formulation and clinical samples for EUCODIS’s most advanced pharmaceutical projects.EUCODIS have recently signed a co-development and licensing agreement with MDI, Salt Lake City, Utah, USA, to develop a topical treatment for breast cancer based on formestane, a potent aromatase inhibitor for treatment and prophylaxis of breast cancer. Under the terms of this license EUCODIS is responsible for the clinical phase II developmental program. The agreement will combine EUCODIS’s experience in clinical development with the expertise of
NextPharma in drug development and clinical sample supply.
“We are delighted to work along side NextPharma as a partner to facilitate our clinical development program,” said Wolfgang Schoenfeld, EUCODIS Chief Executive Officer. “NextPharma’s world leading expertise in formulation development, supply of clinical samples and its expertise and abilities to comply with European and US standards in drug manufacturing are of utmost importance to EUCODIS.”
“At NextPharma we believe our ability to service customers plays an integral part in building lasting relationships and we are very excited at the prospect of working with EUCODIS on this project”, commented Bill Wedlake, CEO, NextPharma Technologies. “One of NextPharma’s great strengths is our ability to adapt and to support our clients regardless of the size or scale of their projects. We look forward to having the opportunity to expand our relationship with EUCODIS into the future - on their biotech, analytical or pharmaceutical development business, where we can employ a wide spectrum of technologies from across our development and manufacturing facilities in Europe.”
About NextPharma
NextPharma Technologies is a leading independent supplier in the fast growing pharmaceutical and biotech product development, clinical trials supplies, manufacturing and logistics outsourcing sector. It has five product development, seven manufacturing and five logistics facilities based in Austria, Belgium, France, Germany and Switzerland employing over 1,200 people. Across these locations Nextpharma has extensive knowledge in the manufacture and development of cytostatics, hormones, antibiotics, pellets, sterile technologies, solid and dry dosage forms and semi-solid and liquid technologies. NextPharma has a customer base, which includes many of the world’s leading pharmaceutical, specialty pharma and biotech companies. NextPharma’s principal shareholder is Credit Suisse First Boston Private Equity.
About Eucodis
Founded in 2004, Eucodis Forschungs– und Entwicklungs GmbH (Vienna, Austria) is a biotechnology company generating novel products in the life science area by applying two powerful technologies mimicking natural processes of evolution: in vivo recombination and somatic hypermutation. Eucodis’ activities focus on two business units, industrial enzymes and pharmaceuticals; beside formestane cream two biopharmaceuticals stemming out of the internal research pipeline are currently profiled to enter preclinical development in 2007.
Contact:
Franck Latrille
Chief Executive Officer
NextPharma Technologies Holding Limited
Tel.: +44 (0) 1483 479 120
Notes to Editors:
About NextPharma
NextPharma Technologies, headquartered in the UK and founded in 2000, is world class provider of product development, contract manufacturing and distribution outsourcing services to the pharmaceutical, specialty pharmaceutical, generics and biotech industry.
It offers a broad range of services from early phase product development, through clinical trials supplies to high volume commercial manufacturing. NextPharma is a world leader in lyophilization, sterile fill-finish and pellet technologies and in specialist product manufacturing including cytotoxics, hormones, penicillins, cephalosporins and controlled substances. Its sterile development and production offers a full range of drug delivery technologies including pre-filled syringes, vials and ampoules.
NextPharma operates globally with seven product development centres, seven manufacturing plants and six storage and distribution sites across Europe and North America employing over 1,200 people. Across these locations NextPharma has built-up a strong track record in the development and manufacture of cytotoxics, hormones, antibiotics, pellets, sterile, solid, semi-solid, liquid and dry dosage forms, supplying customers in North America, Europe and Japan.
NextPharma has a customer base, which includes many of the world's leading pharmaceutical, specialty pharma and biotech companies.